{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:24:03Z","timestamp":1760016243181,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13256-017-1366-4","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T06:11:54Z","timestamp":1502345514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-4702","authenticated-orcid":false,"given":"Kenji","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Manaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunpei","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisei","family":"Mitsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hamasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuta","family":"Nishitai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,18]]},"reference":[{"issue":"9863","key":"1366_CR1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303\u201312.","journal-title":"Lancet"},{"issue":"1","key":"1366_CR2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3892\/ol.2015.3905","volume":"11","author":"K Kawasaki","year":"2016","unstructured":"Kawasaki K, Hamamoto Y, Adachi M, Kanai T, Takaishi H. Early tumor cavitation with regorafenib in metastatic colorectal cancer: a case report. Oncol Lett. 2016;11(1):231\u20133.","journal-title":"Oncol Lett"},{"key":"1366_CR3","first-page":"357","volume":"7","author":"R Tang","year":"2015","unstructured":"Tang R, Kain T, Herman J, Herman J, Seery T. Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report. Cancer Manag Res. 2015;7:357\u201360.","journal-title":"Cancer Manag Res"},{"key":"1366_CR4","volume-title":"The TNM classification of malignant tumours","year":"2009","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind CH, editors. The TNM classification of malignant tumours. 7th ed. Hoboken, NJ: Wiley-Blackwell; 2009.","edition":"7"},{"key":"1366_CR5","unstructured":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2006 for treatment of colorectal cancer. Kanahara. Tokyo. 2006."},{"issue":"6","key":"1366_CR6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10(6):559\u201368.","journal-title":"Lancet Oncol"},{"key":"1366_CR7","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0","author":"U.S. Department of Health and Human Services","year":"2010","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Washington, DC: U.S. Department of Health and Human Services; 2010."},{"issue":"2","key":"1366_CR8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1366_CR9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16(6):619\u201329.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1366_CR10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000382067","volume":"38","author":"RD Hofheinz","year":"2015","unstructured":"Hofheinz RD, Arnold D, Kubicka S, Prasnikar N, Vogel A. Improving patient outcomes with regorafenib for metastatic colorectal cancer\u2014patient selection, dosing, patient education, prophylaxis, and management of adverse events. Oncol Res Treat. 2015;38(6):300\u20138.","journal-title":"Oncol Res Treat"},{"issue":"4 Suppl","key":"1366_CR11","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1200\/jco.2016.34.4_suppl.680","volume":"34","author":"Y Komatsu","year":"2016","unstructured":"Komatsu Y, Muro K, Yamaguchi K, Uetake H, Satoh T, Yoshino T, et al. Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: interim result from postmarketing surveillance (PMS) [abstract]. J Clin Oncol. 2016;34(4 Suppl):680.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-017-1366-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T02:55:28Z","timestamp":1569984928000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-017-1366-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,18]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1186\/s13256-017-1366-4","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2017,8,18]]},"article-number":"227"}}